Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569140 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 1 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00569140: Completed Phase 1 study, sponsored by Ophthotech Corporation.
NCT00569140 is a Phase 1 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00569140, a Phase 1 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of E10030 intravitreous injection when administered as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Interventions
- DRUG E10030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569140
The ClinicalTrials.gov registry entry for NCT00569140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E10030 is the first listed.
NCT00569140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569140 about?
NCT00569140 is a clinical study titled "A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration". The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of E10030 intravitreous injection when administered as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular d...
What is the current status of trial NCT00569140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00569140?
The interventions under investigation include: E10030 (DRUG).
Who is sponsoring clinical trial NCT00569140?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.